BIND

Oppenheimer Comments On 2 Biotech Stocks – Benzinga

Related CNCOppenheimer Boosting Targets In Healthcare On ‘Exposure To Interest Rate Changes’8 Managed Care Stocks To Watch In Earnings Season’Non-Cyclical Consumer Healthcare’: How This Sector Will Create Long-Term Wealth(Seeking Alpha)Related Biotech: Anatomy Of An Investing Mania?Bind Therapeutics Rallies Off Oppenheimer RatingIn separate reports, Oppenheimer analysts commented on the pipelines of two Biotech majors – Centene Corp (NYSE: CNC) and BIND […]

5 Biotech Stocks On JMP's Radar

In a recent report, analysts at JMP Securities discussed five biotech names that are on their radar. Here’s a breakdown of what they had to say.
BIND Therapeutics Inc (NASDAQ: BIND)
BIND will be presenting three posters on its Accurin technology at the American Association of Cancer Research (AACR) meeting in Philadelphia in April.Although the Accurin data the company will be showcasing […]

BIND Therapeutics’ (BIND) CEO Scott Minick on Q1 2014 Results – Earnings Call Transcript

[at Seeking Alpha] – Scott Minick Thank you, Paul, and good morning, everyone. We are very pleased with the way the year has started for BIND. First let me start with BIND-014. We are initiating a 20 patient study in non-small … moreView todays social media effects on BINDView the latest stocks trending across Twitter. Click to view dashboardSee who […]

BIND Therapeutics Reports First Quarter 2014 Financial Results and Updates BIND-014 Clinical Development Plan

[Business Wire] – BIND Therapeutics, Inc. , a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today reported financial moreView todays social media effects on BINDView the latest stocks trending across Twitter. Click to view dashboardSee who BIND is hiring next, click here to view […]

BIND Therapeutics to Present at UBS Global Healthcare Conference

[Business Wire] – BIND Therapeutics, Inc. , a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced today that Scott Minick, BIND’s President and CEO, is scheduled to present at the UB moreView todays social media effects on BINDView the latest stocks trending across Twitter. Click to view dashboardSee who BIND is hiring next, click here to […]